Creganna-Tactx Opens at Cleveland Clinic Incubator

Creganna-Tactx Medical has announced the opening of a new office at Cleveland Clinic’s, Global Cardiovascular Innovation Centre (GCIC). The company was invited to open an office in the new incubator to support companies commercializing innovative medical device technology. The office will provide product development support to early stage companies and also link Creganna-Tactx’s customers to the leaders in medical innovation and healthcare delivery.

From this strategic location on the grounds of the Cleveland Clinic, the company can facilitate connections to industry leading physicians and provide its customers with enhanced design and development support, end-user feedback, device testing and support for pre-clinical studies and clinical trials. This service will be further bolstered by the company’s recent joint venture agreement with Boston Biomedical Associates (BBA), who will work in partnership with Creganna-Tactx Medical to support customers with clinical, regulatory and quality affairs.

Creganna-Tactx Medical develops less invasive devices for the top medical device OEM’s and is one of the largest global contract design and outsourced manufacturing companies.  Commenting on today’s announcement, Randall Sword, Business Development at Creganna-Tactx Medical, said “This move strategically positions Creganna-Tactx Medical to offer our customers complete support along the full product lifecycle.  Working with Cleveland Clinic’s GCIC, we can help bridge the gap between the designer and end-user physician in the development process.”

The GCIC, located on Cleveland Clinic’s main campus, is an incubator facility supporting the development and commercialization of cardiovascular innovations and medical technologies. According to Chris Coburn, Executive Director of Cleveland Clinic Innovations, “Having Creganna-Tactx Medical as part of the Clinic team is an important milestone for us. They will provide benefit to GCIC companies and will collaborate with Clinic innovators as we jointly work to develop products that benefit patients in need.”

Following this announcement, the company will focus on supporting its customers with preclinical research and development support, particularly in the area of Atrial Fibrillation.